# Hutchmed clinical trials: 51 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials with Hutchmed as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Hutchmed: 51 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hutchmed

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07912398 | HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations | Hutchmed | Phase 3 | Not yet recruiting | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912398) |
| July 22, 2026 | NCT07718581 | HMPL-A830 in Solid Tumors | Hutchmed | Phase 1/2 | Recruiting | Solid Tumor, Adult | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718581) |
| July 13, 2026 | NCT07697157 | The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets | Hutchmed | Phase 1 | Completed | Health, Subjective | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697157) |
| June 12, 2026 | NCT07644442 | Study on \[14C\]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male Subjects | Hutchmed | Phase 1 | Completed | Mass Balance Study | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644442) |
| June 11, 2026 | NCT07643272 | A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules | Hutchmed | Phase 1 | Completed | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643272) |
| February 13, 2026 | NCT07409428 | A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL | Hutchmed | Phase 3 | Recruiting | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409428) |
| February 9, 2026 | NCT07396584 | HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor | Hutchmed | Phase 1/2 | Recruiting | Solid Tumors, Adult | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396584) |
| January 16, 2026 | NCT07348133 | Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets | Hutchmed | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348133) |
| January 9, 2026 | NCT07331194 | Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans | Hutchmed | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331194) |
| November 14, 2025 | NCT07228247 | A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | Hutchmed | Phase 1/2 | Recruiting | Solid Tumors, Adult | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228247) |
| June 17, 2025 | NCT07025018 | Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations | Hutchmed | Phase 1 | Recruiting | Gliomas Harboring IDH1 and/or IDH2 Mutations | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07025018) |
| November 4, 2024 | NCT06671873 | Study on Mass Balance of \[14C\]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects | Hutchmed | Phase 1 | Completed | Mass Balance Study | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06671873) |
| September 19, 2024 | NCT06601504 | Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL | Hutchmed | Phase 2 | Completed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06601504) |
| September 4, 2024 | NCT06584032 | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer | Hutchmed | Phase 3 | Recruiting | Advanced Endometrial Cancer | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06584032) |
| April 26, 2024 | NCT06387082 | A Clinical Study of HMPL-506 in Patients With Hematological Malignancies | Hutchmed | Phase 1 | Recruiting | Hematological Malignancies | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06387082) |
| April 26, 2024 | NCT06387069 | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | Hutchmed | Phase 3 | Recruiting | Acute Myeloid Leukemia | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06387069) |
| April 12, 2024 | NCT06361888 | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in... | Hutchmed | Phase 2/3 | Recruiting | Metastatic Pancreatic Cancer | 502 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06361888) |
| March 4, 2024 | NCT06291415 | The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) | Hutchmed | Phase 1 | Withdrawn | Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06291415) |
| July 5, 2023 | NCT05930119 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | Hutchmed | Phase 1 | Completed | Intrahepatic Cholangiocarcinoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05930119) |
| June 2, 2023 | NCT05886374 | A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | Hutchmed | Phase 1 | Unknown | Advanced Malignant Solid Tumors | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05886374) |
| March 23, 2023 | NCT05781906 | Human Mass Balance of \[14C\]HMPL-523 in Healthy Adult Male Chinese Subjects | Hutchmed | Phase 1 | Completed | Imumune Thrombocytopenia(ITP) Human Mass Balance | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05781906) |
| February 9, 2023 | NCT05720767 | HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study | Hutchmed | Phase 1 | Completed | Relapsed or Refractory Lymphoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05720767) |
| February 6, 2023 | NCT05713110 | A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma | Hutchmed | Phase 2 | Completed | Relapsed/Refractory Lymphoma | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05713110) |
| November 2, 2022 | NCT05602597 | HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI | Hutchmed | Phase 1 | Completed | Relapsed or Refractory Lymphoma | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05602597) |
| October 7, 2022 | NCT05571787 | HMPL-523 Food Effect and Proton Pump Inhibitor Study | Hutchmed | Phase 1 | Completed | Relapsed or Refractory Lymphoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05571787) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 26 |
| Phase 1/2 | 9 |
| Phase 2 | 4 |
| Phase 2/3 | 4 |
| Phase 3 | 6 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Recruiting | 10 |
| Terminated | 7 |
| Active not recruiting | 2 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| No longer available | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma | 7 |
| Recurrence | 4 |
| Neuroendocrine Tumors | 4 |
| Colorectal Neoplasms | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Sarcoma | 3 |
| Endometrial Neoplasms | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Cholangiocarcinoma | 2 |
| Glioma | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Triple Negative Breast Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Hodgkin Disease | 1 |
| Renal Insufficiency | 1 |
| Pancreatic Neoplasms | 1 |
| Lymphoma, B-Cell | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Blood Platelet Disorders | 1 |
| Hematologic Diseases | 1 |
| Purpura, Thrombocytopenic | 1 |
| Purpura | 1 |
| Blood Coagulation Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ferry boat companies in the United States](https://specstream.ai/data/businesses/ferry-boat-companies/united-states)
- [Plasterers in the United States](https://specstream.ai/data/businesses/plasterers/united-states)
- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
- [Forklift dealers in the United States](https://specstream.ai/data/businesses/forklift-dealers/united-states)
- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [B2B oil and gas companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-companies/united-states)
